Randomized Double-blind Placebo-controlled Phase 3 Study to Evaluate the Efficacy and Safety of Maralixibat (SHP625) in the Treatment of Subjects With Progressive Familial Intrahepatic Cholestasis (PFIC)
Not yet recruiting
Phase of Trial: Phase III
Latest Information Update: 07 Nov 2018
At a glance
- Drugs Lopixibat chloride (Primary)
- Indications Intrahepatic cholestasis
- Focus Registrational; Therapeutic Use
- Sponsors Shire
- 07 Nov 2018 According to a Mirum Pharmaceuticals media release , the company plans to initiate this trial in 2019
- 10 May 2018 Planned End Date changed from 29 Jun 2020 to 15 Jun 2020.
- 10 May 2018 Planned primary completion date changed from 1 Jun 2020 to 15 Jun 2020.